Novocure LtdNASDAQ:NVCR
- LAST PRICE22.0500
- TODAY'S CHANGE (%)-0.1200 (-0.5413%)
- Bid / Lots22.0300/ 2
- Ask / Lots22.0500/ 3
- Open / Previous Close22.1700 / 22.1700
- Day Range
- 52 Week Range
- Volume332,596
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NVCR |
|---|---|---|
| 09:32 ET | 17505 | 22.01 |
| 09:34 ET | 2235 | 21.97 |
| 09:36 ET | 2573 | 22.08 |
| 09:38 ET | 2526 | 22.16 |
| 09:39 ET | 1689 | 22.07 |
| 09:41 ET | 322 | 22.0527 |
| 09:43 ET | 2103 | 21.995 |
| 09:45 ET | 481 | 22.03 |
| 09:48 ET | 16012 | 21.93 |
| 09:50 ET | 1594 | 22 |
| 09:52 ET | 4172 | 21.82 |
| 09:54 ET | 300 | 21.818 |
| 09:56 ET | 7221 | 21.94 |
| 09:57 ET | 20399 | 21.855 |
| 09:59 ET | 2300 | 22.01 |
| 10:01 ET | 1346 | 21.985 |
| 10:03 ET | 1138 | 21.88 |
| 10:06 ET | 18053 | 21.88 |
| 10:08 ET | 7486 | 21.73 |
| 10:10 ET | 1324 | 21.73 |
| 10:12 ET | 6200 | 21.7 |
| 10:14 ET | 24138 | 21.58 |
| 10:15 ET | 6724 | 21.48 |
| 10:17 ET | 1970 | 21.55 |
| 10:19 ET | 2569 | 21.57 |
| 10:21 ET | 2815 | 21.51 |
| 10:24 ET | 819 | 21.5757 |
| 10:26 ET | 6088 | 21.83 |
| 10:28 ET | 3724 | 21.69 |
| 10:30 ET | 2605 | 21.69 |
| 10:32 ET | 9512 | 21.68 |
| 10:33 ET | 3554 | 21.63 |
| 10:35 ET | 644 | 21.68 |
| 10:37 ET | 400 | 21.64 |
| 10:39 ET | 300 | 21.58 |
| 10:42 ET | 1767 | 21.62 |
| 10:44 ET | 479 | 21.64 |
| 10:46 ET | 900 | 21.655 |
| 10:48 ET | 2293 | 21.63 |
| 10:50 ET | 4611 | 21.64 |
| 10:51 ET | 900 | 21.66 |
| 10:53 ET | 1306 | 21.71 |
| 10:55 ET | 550 | 21.7 |
| 10:57 ET | 14420 | 21.775 |
| 11:00 ET | 2864 | 21.83 |
| 11:02 ET | 1804 | 21.815 |
| 11:04 ET | 100 | 21.8 |
| 11:06 ET | 2524 | 21.84 |
| 11:08 ET | 1962 | 21.98 |
| 11:09 ET | 3205 | 22.03 |
| 11:11 ET | 900 | 22.01 |
| 11:13 ET | 700 | 21.96 |
| 11:15 ET | 757 | 21.98 |
| 11:18 ET | 100 | 21.95 |
| 11:20 ET | 900 | 21.99 |
| 11:22 ET | 300 | 21.97 |
| 11:24 ET | 1039 | 22.09 |
| 11:26 ET | 500 | 22.09 |
| 11:27 ET | 850 | 22.14 |
| 11:29 ET | 4097 | 22.17 |
| 11:31 ET | 2580 | 22.09 |
| 11:33 ET | 709 | 22.12 |
| 11:36 ET | 100 | 22.11 |
| 11:38 ET | 780 | 22.11 |
| 11:40 ET | 700 | 22.03 |
| 11:42 ET | 100 | 22.01 |
| 11:44 ET | 1145 | 22.02 |
| 11:45 ET | 400 | 22.05 |
May 2, 2024
DJ Novocure Is Maintained at Neutral by HC Wainwright & Co., from 12:51PM ET on Thursday May 02, 2024 by Dow Jones
12:51PM ET on Thursday May 02, 2024 by Dow JonesNovocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon, from 7:01AM ET on Thursday May 02, 2024 by Dow Jones
7:01AM ET on Thursday May 02, 2024 by Dow JonesNovocure Reports First Quarter 2024 Financial Results, from 7:00AM ET on Thursday May 02, 2024 by Dow Jones
7:00AM ET on Thursday May 02, 2024 by Dow Jones*DJ Novocure 1Q Loss/Shr 36c >NVCR, from 7:00AM ET on Thursday May 02, 2024 by Dow Jones
7:00AM ET on Thursday May 02, 2024 by Dow Jones
Apr 24, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Novocure Ltd | 2.4B | -12.2x | --- |
Inari Medical Inc | 2.7B | -113.0x | --- |
Myriad Genetics Inc | 2.2B | -9.0x | --- |
Rxsight Inc | 2.4B | -47.6x | --- |
STAAR Surgical Co | 2.1B | 138.8x | +31.52% |
UFP Technologies Inc | 2.0B | 41.4x | +24.81% |
Company Information
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
Contact Information
- Headquarters
- No. 4 The Forum, Grenville StreetSAINT HELIER, Jersey JE2 4UF
- Phone
- 153-475-6700
- Fax
- ---
Executives
- Executive Chairman of the Board
- William Doyle
- President, Chief Executive Officer, Director
- Asaf Danziger
- Chief Financial Officer
- Ashley Cordova
- Chief Operating Officer
- Wilhelmus Groenhuysen
- Chief Human Resource Officer
- William Burke
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.4B |
|---|---|
Revenue (TTM) | $525.7M |
Shares Outstanding | 107.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.80 |
EPS | $-1.81 |
Book Value | $3.39 |
P/E Ratio | -12.2x |
Price/Sales (TTM) | 4.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40.74% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
